CHEMOTHERAPY REGIMEN AC (DOXORUBICIN AND CYCLOPHOSPHAMIDE) IN BREAST CANCER – PREVENTION OF NAUSEA AND VOMITING

CHEMOTHERAPY REGIMEN AC (DOXORUBICIN AND CYCLOPHOSPHAMIDE) IN BREAST CANCER – PREVENTION OF NAUSEA AND VOMITING

Chemotherapy regimen AС (doxorubicin and cyclophosphamide) is the most often used in adjuvant chemotherapy of breast cancer. AC regimen is high emetogenic.Objective – to evaluate the effectiveness of the combination of aprepitant, ondansetron and dexamethasone for the prevention of nausea and vomiti...

Full description

Bibliographic Details
Main Authors:	I. A. Koroleva, M. V. Kopp, E. M. Lipaeva
Format:	Article
Language:	Russian
Published:	Remedium Group LLC 2017-11-01
Series:	Медицинский совет
Subjects:	breast cancer chemotherapy regimen (doxorubicin and cyclophosphamide) aprepitant
Online Access:	https://www.med-sovet.pro/jour/article/view/2175

Similar Items

Evaluation of the effectiveness of aprepitant for prevention of nausea and vomiting in patients with breast cancer
by: I. A. Koroleva, et al.
Published: (2018-11-01)

A randomized study of olanzapine-containing versus standard antiemetic regimens for the prevention of chemotherapy-induced nausea and vomiting in Chinese breast cancer patients
by: Winnie Yeo, et al.
Published: (2020-04-01)

Influence of trimetazidine on myocardium energy balance during chemotherapy with doxorubicin and cyclophosphamide
by: A. A. Avagimyan
Published: (2022-06-01)

Efficacy of the combination use of aprepitant and palonosetron for improving nausea in various moderately emetogenic chemotherapy regimens
by: Naohisa Yoshida, et al.
Published: (2019-01-01)

Single‐dose NEPA versus an aprepitant regimen for prevention of chemotherapy‐induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy
by: Laurent Zelek, et al.
Published: (2023-08-01)

Evaluation of a neurokinin-1 antagonist in preventing multiple-day cisplatin-induced nausea and vomiting
by: Li Quanfu, et al.
Published: (2018-03-01)

Combination Antiemetic Therapy for Chemotherapy-Induced Nausea and Vomiting in Patients with NSCLC Receiving Carboplatin-Based Chemotherapy
by: Shimokawa M, et al.
Published: (2022-09-01)

Quality of Life in Breast Cancer Patients using Neoadjuvant AC (Doxorubicin and Cyclophosphamide) in Comparison with PG (Paclitaxel and Gemcitabine) Therapy
by: Aziz Rezapour, et al.
Published: (2018-01-01)

Cost-Effectiveness of Aprepitant in Preventing Chemotherapy-Induced Nausea and Vomiting: A Systematic Review of Published Articles
by: Tingting Qiu, et al.
Published: (2021-08-01)

Efficacy and toxicity of doxorubicin and cyclophosphamide for the neoadjuvant treatment of locally advanced stage canine mammary tumors
by: Fikriye Ecem KURUOGLU, et al.
Published: (2020-09-01)

Efficacy, safety and feasibility of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric patients receiving moderately and highly emetogenic chemotherapy – results of a non-interventional observation study
by: Semjon Willier, et al.
Published: (2019-11-01)

Efficacy of the oral neurokinin-1 receptor antagonist aprepitant administered with ondansetron for the prevention of postoperative nausea and vomiting
by: Chae Seong Lim, et al.
Published: (2013-03-01)

Chromonychia Secondary to Chemotherapy
by: Marien Lopes, et al.
Published: (2013-06-01)

A case of doxorubicin and cyclophosphamide therapy-induced type 1 diabetes: a case report
by: Makoto Miyabayashi, et al.
Published: (2023-01-01)

Quality of Life of Breast Cancer Women During Chemotherapy with Fluorouracil, Doxorubicin and Cyclophosphamide (FAC) Regimen
by: Sophit Korpunsilp, et al.
Published: (2017-10-01)

Efficacy of NEPA, a fixed antiemetic combination of netupitant and palonosetron, vs a 3‐day aprepitant regimen for prevention of chemotherapy‐induced nausea and vomiting (CINV) in Chinese patients receiving highly emetogenic chemotherapy (HEC) in a randomized Phase 3 study
by: Jianhua Chang, et al.
Published: (2020-07-01)

Aprepitant plus palonosetron versus dexamethasone plus palonosetron in preventing chemotherapy-induced nausea and vomiting in patients with moderate-emetogenic chemotherapy: A randomized, open-label, phase 3 trial
by: Yi Cheng, et al.
Published: (2022-07-01)

A study on the efficacy and safety of aprepitant injection in preventing and treating nausea and vomiting induced by platinum‐based chemotherapy in lung cancer
by: Yan Fei, et al.
Published: (2024-03-01)

Evaluating Aprepitant single-dose plus granisetron and dexamethasone in children receiving highly emetogenic chemotherapy for the prevention of chemotherapy-induced nausea and vomiting: A triple-blinded randomized clinical trial
by: Aziz Eghbali, et al.
Published: (2023-07-01)

The cost-effectiveness of neoadjuvant chemotherapy in women with locally advanced breast cancer: Adriamycin and cyclophosphamide in comparison with paclitaxel and gemcitabine
by: Javad Javan-Noughabi, et al.
Published: (2018-01-01)

Granisetron plus aprepitant versus granisetron in preventing nausea and vomiting during CHOP or R-CHOP regimen in malignant lymphoma: a retrospective study
by: Yoshinori Wakasugi, et al.
Published: (2019-11-01)

Aprepitant in combination with palonosetron for the prevention of postoperative nausea and vomiting in female patients using intravenous patient-controlled analgesia
by: Jae Hwa Yoo, et al.
Published: (2018-12-01)

Effect of combinations of dexamethasone-ondansetron and dexamethasone-ondansetron-aprepitant versus aprepitant alone for early postoperative nausea and vomiting after day care gynaecological laparoscopy: A randomised clinical trial
by: Ingilala L Thanuja, et al.
Published: (2021-01-01)

Risk Factors Associated with Chemotherapy-Induced Nausea and Vomiting Among Women with Breast Cancer Receiving Highly Emetogenic Chemotherapy: Individual Patient-Based Analysis of Three Prospective Antiemetic Trials
by: Yeo W, et al.
Published: (2024-04-01)

Identification of optimal contemporary antiemetic prophylaxis for doxorubicin-cyclophosphamide chemotherapy in Chinese cancer patients: post-hoc analysis of 3 prospective studies
by: Winnie Yeo, et al.
Published: (2021-08-01)

The experience of preoperative treatment with anthracyclines in patients with luminal-type B locally advanced breast cancer
by: D. Ye. Cherniavskyi, et al.
Published: (2022-09-01)

Effects of ondansetron alone and in combination with domperidone in the prevention of chemotherapy-induced nausea and vomiting in breast cancer patients
by: Kaberi Das Gupta, et al.
Published: (2007-06-01)

Neoadjuvant Doxorubicin-Paclitaxel Combined Chemotherapy in Patients with Inoperable Stage III Breast Cancer: A Retrospective Cohort Study with 10 Years of Follow-Up in Vietnam
by: Duc Thanh Le, et al.
Published: (2023-06-01)

Busulfan/Cyclophosphamide Compared with Melphalan as a Conditioning Regimen for Autologous Transplantation of Multiple Myeloma: A Long-Term Assessment
by: Shiyuan Zhou, et al.
Published: (2023-09-01)

Addition of 3-day aprepitant to ondansetron and dexamethasone for prophylaxis of chemotherapy-induced nausea and vomiting among patients with diffuse large B cell lymphoma receiving 5-day cisplatin-based chemotherapy
by: Raafat Abdel-Malek, et al.
Published: (2017-09-01)

An observational study of dose dense chemotherapy with lipegfilgrastim support in early breast cancer
by: Ahmed Rashed, et al.
Published: (2023-02-01)

APF530 versus ondansetron, each in a guideline-recommended three-drug regimen, for the prevention of chemotherapy-induced nausea and vomiting due to anthracycline plus cyclophosphamide–based highly emetogenic chemotherapy regimens: a post hoc subgroup analysis of the Phase III randomized MAGIC trial
by: Schnadig ID, et al.
Published: (2017-05-01)

The efficacy of combination of ondansetron and aprepitant on preventing the radiotherapy-induced nausea and vomiting
by: Hamid Emami, et al.
Published: (2015-01-01)

Assessing the impact of aprepitant and ondansetron on postoperative nausea and vomiting in orthognathic surgeries: a randomized controlled trial
by: Mostafa Alam, et al.
Published: (2023-12-01)

THE EFFICACY OF APREPITANT (NK-1 RECEPTOR ANTAGONIST) AS PROPHYLAXIS FOR POSTOPERATIVE NAUSEA AND VOMITING
by: Muhammad Akram, et al.
Published: (2020-04-01)

Aprepitant versus ondansetron in preoperative triple-therapy treatment of nausea and vomiting in neurosurgery patients: study protocol for a randomized controlled trial
by: Bergese Sergio, et al.
Published: (2012-08-01)

Comparative evaluation of doxorubicin, cyclophosphamide, 5-fluorouracil, and cisplatin on cognitive dysfunction in rats: Delineating the role of inflammation of hippocampal neurons and hypothyroidism
by: Lamis I. Alotayk, et al.
Published: (2023-09-01)

Validation of different personalized risk models of chemotherapy‐induced nausea and vomiting: results of a randomized, double‐blind, phase III trial of fosaprepitant for cancer patients treated with high‐dose cisplatin
by: Yuanyuan Zhao, et al.
Published: (2023-02-01)

The Prosigna gene expression assay and responsiveness to adjuvant cyclophosphamide-based chemotherapy in premenopausal high-risk patients with breast cancer
by: Maj-Britt Jensen, et al.
Published: (2018-07-01)

Postoperative nausea and vomiting in patients undergoing colorectal surgery within an institutional enhanced recovery after surgery protocol: comparison of two prophylactic antiemetic regimens
by: Jennifer Holder-Murray, et al.
Published: (2019-08-01)